Obesity, overweight Obesity, overweight
Conditions
Interventions
For this study 3 groups will be included: 1) lean individuals consuming a low-glycaemic meal (n=8)
2) lean individuals consuming a high-glycaemic meal (n=8)
and 3) individuals with obesity consuming a high-glycaemic meal (n=8). All participants (n=18
n=6 will be recruited as reserve) will ingest during the study a 14C-glucose labelled drink. During the study, participants will stay at the laboratory of Human and Animal Physiology at Wageningen Uni
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Healthy males and females using contraception during and for 3 months after the study.Aged from 18-65 years at the time of signing informed consent18.5 < BMI < 25 kg·m2 or 30< BMI <35 kg·m2Must be willing and able to communicate and participate in the whole study, including consumption of 14C-glucose and meals offered during study conductMust have regular bowel movements (i.e. average stool production of =1 and =3 stools per day)Must usually eat 3 meals per day (i.e. breakfast, lunch and dinner)
Exclusion criteria
Exclusion criteria: Diabetes (Type 1, Type 2, or genetic form of diabetes) Any diagnosed cardiovascular (heart) disease or high blood pressure (=140 mmHg systolic and/or =90 mmHg diastolic)HbA1c higher than 53 mmol/molHistory of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastro-intestinal disease, immunodeficiency, endocrine, neurological, or psychiatric disordersAny diagnosed respiratory disease, such as COPD or asthmaAny previous motor disorders or disorders in muscle and/or lipid metabolismKnown severe kidney problemsPresence of an ulcer in the stomach or gut and/or strong history of indigestionRecent or chronic history of diarrhoeaKnown anaemiaA personal or family history of thrombosis (clots), epilepsy, seizures, or schizophrenia.Regular use of dietary supplements (>3 times per week)Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices)History of any drug or alcohol abuse in the past two yearsA confirmed positive alcohol breath test at screening or admissionDrug useClaustrophobiaSubjects who are on a weight loss diet or following a high calorific/high protein diet to gain weightSubjects with functional constipationAny known food allergies or intolerances to the 14 major food allergens (celery, cereals containing gluten, crustaceans, eggs, fish, lupin, milk, molluscs, mustard, tree nuts, peanuts, sesame seeds, soybeans, sulphur dioxide and sulphites) or history of a malabsorption syndrome including coeliac diseaseSubjects who have regular gastrointestinal complaints including abdominal pain, stomach upsets and borborygmi or known or suspected irritable bowel syndromeCurrently taking part in another scientific researchHaving received a product with 14C in the past 12 monthsPregnant or breastfeedingSmoking or having used nicotine-containing products in the 6 months prior to the study.Subjects who have taken antibiotics within the 60 days prior to the adaptation period.Currently involved in a structured progressive resistance training programme (>3 times per week)Sedentary lifestyle as assessed using the International Physical Activity Questionnaire [IPAQ].Unable to give consentEmployed or undertaking a thesis or internship at the department of Human and Animal Physiology
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include de novo lipogenesis from glucose, mass balance recovery/caloric value of glucose (from expired CO2), content of 14C labelled metabolites in the carbohydrate metabolism pathways, energy expenditure and whole-body substrate utilisation (i.e. carbohydrate and lipid oxidation) in fasted conditions and following ingestion of a high vs low glycaemic meal (via indirect calorimetry), and forearm balance of 14C-glucose and metabolites following ingestion of a high vs glycaemic meal. | — |
Primary
| Measure | Time frame |
|---|---|
| The main study parameter/endpoint is polyol pathway activity and metabolism, measured as 14C concentration of glucose, fructose, and intermediate metabolites via Accelerator Mass Spectrometry (AMS). | — |
Countries
Netherlands
Contacts
Public ContactM.L. Dirks
Wageningen Universiteit
Outcome results
None listed